# Lycia Therapeutics (LYCA) — News

LYCA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lyca/news

## Recent headlines

- [Lycia Therapeutics opens at $28.55, IPO at $18](https://www.ainvest.com/news/lycia-therapeutics-opens-28-55-ipo-18-2610) — AInvest Wire, Oct 23, 2026
  Lycia Therapeutics Inc (LYCA) made its initial public offering (IPO) on October 21, 2026, with a listing price of $18 per share. The stock opened for trading on October 21 at $28.55, reflecting strong investor demand and optimism about the company’s clinical-stage biotechnology platform. As of…
- [Lycia Therapeutics shares indicated at $27.47; IPO price $18](https://www.ainvest.com/news/lycia-therapeutics-shares-27-47-ipo-price-18-2610) — AInvest Wire, Oct 23, 2026
- [Lycia Therapeutics shares indicated to open at $20, IPO $18](https://www.ainvest.com/news/lycia-therapeutics-shares-open-20-ipo-18-2610) — AInvest Wire, Oct 23, 2026
  Lycia Therapeutics, a biotechnology company developing targeted protein degradation therapies, has set an initial public offering (IPO) price range of $16 to $18 per share, with shares potentially opening at $20 in early trading. The company plans to offer 14.7 million shares on the Nasdaq under…
- [Lycia said to allocate zero shares to half of orders in IPO](https://www.ainvest.com/news/lycia-allocate-shares-orders-ipo-2610) — AInvest Wire, Oct 23, 2026
  Lycia Therapeutics, Inc. (LYCA), a biotechnology company focused on developing protein degrader therapies, is preparing for its initial public offering (IPO) . Recent reports indicate that the company plans to allocate zero shares to half of the orders received during the IPO process. This approach…
- [Lyca IPO security released for quotation](https://www.ainvest.com/news/lyca-ipo-security-released-quotation-2610) — AInvest Wire, Oct 23, 2026
  Lycia Therapeutics Inc. (LYCA) has announced that its initial public offering (IPO) securities have been released for quotation. This development marks a significant milestone for the biopharmaceutical company, which is focused on the discovery and development of novel therapeutics. The release of…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).